| P50 | author | Ke-Da Yu | Q88152186 |
| P2093 | author name string | Lei Fan | |
| | Hong-Wei Zhang | |
| | Jiong Wu | |
| | Zhen Hu | |
| | Zhi-Ming Shao | |
| | Guang-Yu Liu | |
| | Gen-Hong Di | |
| | Li-Chen Tang | |
| | Yi-Feng Hou | |
| | Zhen-Zhou Shen | |
| | Zhi-Gang Zhuang | |
| | Si-Yu Wu | |
| | Can-Ming Chen | |
| | Ke-Jin Wu | |
| P2860 | cites work | New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) | Q28131668 |
| | Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 | Q30543788 |
| | Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial | Q33160892 |
| | Ki67 expression and the effect of neo-adjuvant chemotherapy on luminal HER2-negative breast cancer | Q34012047 |
| | Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-bas | Q35023441 |
| | Adjuvant ovarian suppression in premenopausal breast cancer | Q35124558 |
| | Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up | Q35607675 |
| | A Comparison of Visual Assessment and Automated Digital Image Analysis of Ki67 Labeling Index in Breast Cancer | Q35940233 |
| | Autophagy inhibition re-sensitizes pulse stimulation-selected paclitaxel-resistant triple negative breast cancer cells to chemotherapy-induced apoptosis | Q36609034 |
| | Side effects of standard adjuvant and neoadjuvant chemotherapy regimens according to age groups in primary breast cancer | Q37677748 |
| | Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis | Q38188183 |
| | Concurrent versus sequential adjuvant chemo-endocrine therapy in hormone-receptor positive early stage breast cancer patients: a systematic review and meta-analysis | Q38866320 |
| | Changes in PgR and Ki-67 in residual tumour and outcome of breast cancer patients treated with neoadjuvant chemotherapy. | Q44100959 |
| | A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival | Q44682357 |
| | Survival outcome and reduction rate of Ki-67 between pre- and post-neoadjuvant chemotherapy in breast cancer patients with non-pCR. | Q45173811 |
| | Preoperative concurrent chemo- and endocrine therapies for women with large operable breast cancer expressing steroid hormone receptors | Q46506423 |
| | Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial | Q46585161 |
| | Neoadjuvant letrozole for postmenopausal estrogen receptor-positive, HER2-negative breast cancer patients, a study from the Danish Breast Cancer Cooperative Group (DBCG). | Q48247756 |
| | Letrozole plus GnRH analogue as preoperative and adjuvant therapy in premenopausal women with ER positive locally advanced breast cancer. | Q51733625 |
| | Ki67 Changes Identify Worse Outcomes in Residual Breast Cancer Tumors After Neoadjuvant Chemotherapy. | Q52680900 |
| | Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM/2006-03, a multicenter, randomized, phase-II study. | Q54506148 |
| | The residual tumor autophagy marker LC3B serves as a prognostic marker in local advanced breast cancer after neoadjuvant chemotherapy. | Q54725262 |
| | De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017 | Q57116621 |
| | Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update | Q57130157 |
| | Pathological complete response rates following different neoadjuvant chemotherapy regimens for operable breast cancer according to ER status, in two parallel, randomized phase II trials with an adaptive study design (ECTO II) | Q57579916 |
| | Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer | Q57579999 |
| | The efficacy and safety of neoadjuvant chemotherapy +/− letrozole in postmenopausal women with locally advanced breast cancer: a randomized phase III clinical trial | Q61852571 |
| | Antagonism of chemotherapy-induced cytotoxicity for human breast cancer cells by antiestrogens | Q69601253 |
| | Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer | Q79572358 |
| | Avoidance of Negative Results in Adjuvant Endocrine Therapy Trials for Estrogen Receptor-Positive Breast Cancer | Q88238618 |
| P433 | issue | 13 | |
| P921 | main subject | multicenter clinical trial | Q6934595 |
| P1104 | number of pages | 9 | |
| P304 | page(s) | 2185-2193 | |
| P577 | publication date | 2019-03-20 | |
| P1433 | published in | Cancer | Q326041 |
| P1476 | title | Concurrent neoadjuvant chemotherapy and estrogen deprivation in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer (CBCSG-036): A randomized, controlled, multicenter trial | |
| P478 | volume | 125 | |